Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bactoblis EVOL
- Development stage
- Unknown
- Lead developer
- Pharmextracta
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bactoblis EVOL is an advanced oral probiotic formulation designed to support the health of the upper respiratory tract and oral cavity. It is an evolution of the original Bactoblis formula, typically containing a high concentration of the specific probiotic strain *Streptococcus salivarius* K12 (BLIS K12) in combination with Vitamin D3 (cholecalciferol). The K12 strain is a naturally occurring commensal bacterium that colonizes the oral cavity and produces bacteriocin-like inhibitory substances (BLIS), specifically salivaricin A2 and B, which actively inhibit the growth of common pathogens such as *Streptococcus pyogenes* and *Streptococcus pneumoniae*. By restoring the oral microbiome balance and providing Vitamin D for immune system support, Bactoblis EVOL is used to reduce the recurrence of pharyngitis, tonsillitis, and otitis media, as well as to improve oral hygiene and manage halitosis. It is formulated as orosoluble tablets to ensure prolonged contact with the oral mucosa.
- Brand names
- Bactoblis EVOLBactoblis
- Other names
- Streptococcus salivarius K12 + Vitamin D3
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Bactoblis EVOL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bactoblis EVOL.